The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...

Venture Capital firm Asabys Partners closed its second fund, Sabadell Asabys Health Innovation Investments II, with total commitments of €180 million ($200 million). The funds will go towards 12 to 15 ...

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial ...

Both chambers of the U.S. Congress put aside their election year politicking Sept. 25 long enough to pass a continuing ...

Neuros Medical Inc.’s Altius direct electrical nerve stimulation system significantly reduced pain in 30 minutes and ...

Breakthrough – or even better, revolutionary breakthrough – is perhaps the most overused term in drug development. But the ...

Researchers from Moderna Inc. and affiliated organizations presented preclinical data for the novel mRNA-lipid nanoparticle ...

Biomedicines Inc. and its artificial intelligence platform to generate drugs for multiple undisclosed targets. The number of targets and therapeutic areas also weren’t disclosed. Novartis will pick ...

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...

Mental tech startup Doctorpresso Co. Ltd. launched an audio journaling mobile application called Redi, in South Korea, as a voice analysis software capable of detecting depression through artificial ...

Researchers at the University North Carolina at Chapel Hill and University of Florida have divulged triazoles acting as κ-opioid receptor agonists reported to be useful for the treatment of pain, ...

The risk and benefit of Pfizer Inc.’s oral sickle cell disease drug Oxbryta (voxelotor) has flipped, prompted by what the company called new clinical data indicating “an imbalance in vaso-occlusive ...